Person:
KILIÇ, ERDEM

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
ERDEM
Last Name
KILIÇ
Name
Email Address
Birth Date

Filters

2014 - 20164
Reset filters

Settings

Author: KILIC, ERDEM × Rights: info:eu-repo/semantics/openAccess ×

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    PublicationOpen Access
    Serum endocan levels in women with restless legs syndrome.
    (2015-11-19) CELIK, K; ÇıKRıKÇıOĞLU, MA; HALAC, G; KILIC, ERDEM; AYHAN, S; OZARAS, N; Karatoprak, CUMALİ; YILDIZ, KEMALETTİN; YILDIZ, RS; ZORLU, MEHMET; CAKIRCA, MUSTAFA; KıSKAÇ, MUHARREM; KILIÇ, ERDEM; YILDIZ, KEMALETTİN; ZORLU, MEHMET; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM
    Background: Endocan is a recently introduced marker of endothelial dysfunction. The objective of this study was to compare serum endocan levels in patients with restless legs syndrome (RLS) and control subjects in order to elucidate whether RLS is associated with endothelial dysfunction. Methods: A total of 31 drug naïve female patients with RLS and 31 age- and BMI-matched women were included in the study. Patients with pathological or physiological conditions or with a history of medication use that could potentially influence endothelial functions were excluded, as well as those with alcohol or drug abuse history. The two groups were compared with routine blood tests and serum endocan levels. Results: Patients with RLS had lower serum endocan levels than the controls (P=0.037). There was a negative bivariate correlation between RLS severity score and serum endocan levels (r=-0.406, P=0.023). While white blood cell count was significantly higher in RLS group, 25-hydroxy vitamin D3, vitamin B12, transferrin saturation rate, and HDL-cholesterol were significantly lower. Creatininemia and diastolic blood pressure were also marginally insignificantly lower in RLS group. Due to the presence of differences between two groups in these variables, a linear regression analysis was performed that showed a positive association between endocan and creatininemia (β=0.310, P=0.022), and a negative association between endocan and RLS (β=-0.502, P,0.001). Conclusion: The results of this study seem to suggest that patients with RLS may have better endothelial functions when compared with the general population and that these patients may be better protected against atherosclerosis
  • Thumbnail Image
    PublicationOpen Access
    Enhancement of Cisplatin sensitivity in human cervical cancer: epigallocatechin-3-gallate.
    (2015-01-26) KILIC, U; SAHIN, K; TUZCU, M; BASAK, N; KUCUK, O; ORHAN, C; Elibol-Can, BİRSEN; KILIC, ERDEM; SAHIN, F; ELİBOL, BİRSEN; KILIÇ, ERDEM; SU KÜÇÜK, ÖZLEM
    Cisplatin is one of the effective chemotherapeutics in the treatment of several types of cancers. However, in addition to the efforts against to its toxicity, the amelioration of cisplatin sensitivity is an important point in treatment of cervical cancer. To do so, additional substances such as epigallocatechin gallate (EGCG), a polyphenol in green tea, have been used in combination with chemotherapeutics. We aimed to investigate the possible molecular pathways to potentiate cervical cancer cell (HeLa) growth inhibition by combination therapy of cisplatin and EGCG. HeLa cells were treated with EGCG (25µM), cisplatin (250 nM), and their combination for 24 h. Cell viability was determined by MTS Assay. We analyzed the expressions of NF-κB p65, COX-2, Nrf2, HO-1, p-mTOR, p-p70S6K1, p-4E-BP1, and p-Akt byWestern blot analysis. Herein, we have demonstrated that EGCG works synergistic with cisplatin in inhibiting growth of cervical cancer cells. EGCG improved efficacy of cisplatin treatment in HeLa cells by regulating NFκB p65, COX-2, p-Akt, and p-mTOR pathways, whereas it increased the expression levels of Nrf2/HO-1 in combined therapy. Our observations revealed that EGCG increases the sensitiz
  • Thumbnail Image
    PublicationOpen Access
    Soluble TNF-Like Weak Inducer of Apoptosis as a New Marker in Preeclampsia: A Pilot Clinical Study.
    (2016-01-01) YILDIRIM, ZEYNEP BEYZA; SUMNU, A; BADEMLER, N; KILIC, ERDEM; SUMNU, G; KARADAG, S; GURSU, MELTEM; OZEL, A; BATMAZ, G; ATES, SEDA; Dane, B; OZTURK, S; YILDIRIM, ZEYNEP BEYZA; KILIÇ, ERDEM; GÜRSU, MELTEM; ATEŞ, SEDA; KILIÇOĞLU DANE, PAKİZER BANU
    ntroduction: All findings of preeclampsia appear as the clinical consequences of diffuse endothelial dysfunction. Soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) was recently introduced as a TNF related cytokine in various inflammatory and noninflammatory disorders. sTWEAK was found to be related to endothelial dysfunction in patients with chronic kidney disease. In our study we aimed to compare sTWEAK levels in women with preeclampsia to corresponding levels in a healthy pregnant control group. Materials and methods: The study was undertaken with 33 patients with preeclampsia and 33 normal pregnant women. The concentration of sTWEAK in serum was calculated with an enzyme linked immunosorbent assay (ELISA) kit. Results: Serum creatinine, uric acid, LDH levels, and uPCR were significantly higher in the patient group compared to the control group. sTWEAK levels were significantly lower in preeclamptic patients (332 ± 144 pg/mL) than in control subjects (412 ± 166 pg/mL) (p = 0.04). Discussion: Our study demonstrates that sTWEAK is decreased in patients with preeclampsia compared to healthy pregnant women. There is a need for further studies to identify the role of sTWEAK in the pathogenesis of preeclampsia and to determine whether it can be regarded as a predictor of the development of preeclampsia.
  • Thumbnail Image
    PublicationOpen Access
    Vaspin and lipocalin-2 levels in severe obsructive sleep apnea.
    (2014-06-01) KıSKAÇ, MUHARREM; ZORLU, MEHMET; AKKOYUNLU, MUHAMMED EMİN; KILIC, ERDEM; CAKIRCA, MUSTAFA; Karatoprak, CUMALİ; YAVUZ, E; ARDIC, C; CAMLI, AHMET ADİL; CIKRIKCIOGLU, M; KART, L; KISKAÇ, MUHARREM; ZORLU, MEHMET; AKKOYUNLU, MUHAMMED EMİN; KILIÇ, ERDEM; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; ÇAMLI, AHMET ADİL
    Background: Vaspin and lipocalin-2 are less-known recent members of adipocytokine family. There are ongoing studies investigating the role of vaspin ve lipocalin-2 in metabolic syndrome (MS). Obstructive sleep apnea syndrome (OSAS) is independently associated with an increased prevalence of MS. We aimed to measure the levels of vaspin and lipocalin-2 which are secreted from adipocytes in patients with severe OSAS and examine the relationship between these two adipocytokines and OSAS. Methods: The study consisted of two groups: severe OSAS patients with an apnea-hypopnea index (AHI) of >30/h (OSAS group, 34 subjects) and age-matched healthy volunteers with a AHI <5/h (control group, 25 subjects) Serum levels of vaspin and lipocalin-2 in these two groups were compared. Results: Serum levels of vaspin were significantly lower in OSAS group; patients with severe OSAS compared with control group; healthy volunteers (OSAS group: 0.69±0.5 vs. control group: 1.24±1.13; P=0.034). The difference between the two groups in terms of serum levels of lipocalin-2 has not reached statistical significance (OSAS group: 61.6±18.2 vs. control group: 68.5±20.1; P=0.17). Conclusions: We found that serum vaspin levels were significantly lower in patients with severe OSAS compared with healthy controls. Lipocalin-2 levels were similar. The decrease in serum vaspin levels in severe OSAS patients may be important in diagnosis and follow-up of these patients.